02279nas 2200577- 450 99622294890331620211118213022.02057-5858(OCoLC)915087449(CKB)3780000000055208(CONSER)--2016229665(DE-599)ZDB2835258-0(NjHacI)993780000000055208(EXLCZ)99378000000005520820150729a20159999 --- -engur|||||||||||txtrdacontentcrdamediacrrdacarrierMicrobial genomics[London] :Society for General Microbiology,2015-London :Microbiology Society1 online resourceRefereed/Peer-reviewedEfficacy and direct costs of chronic hepatitis C treatment with first generation NS3/4A protease inhibitors in a real life population -- Efficacy of HCV treatment in Poland at the turn of the interferon era - the EpiTer study -- Prevalence of HCV genotypes in Poland - the EpiTer study -- Simple non-invasive markers for early diagnosis and determination of the severity of liver diseases -- The influence of anti-HBc status on the sustained virological response rate in HCV-infected patients treated with pegylated interferon alfa 2 and ribavirin -- The occurrence of autoantibodies in patients with chronic HCV infection, including patients dialyzed and after kidney transplantation.MGenMICROB GENOMMicrobial genomicsPeriodicalsGenomicsMicrobial genomicsfast(OCoLC)fst01019505Genome, MicrobialPeriodicals.lcgftPeriodical.Periodicals.fastFulltext.Internet Resources.Periodicals.Microbial genomicsGenomics.Microbial genomics.Genome, Microbial.579.3135Society for General Microbiology,Microbiology Society,NjHacINjHacIJOURNAL996222948903316Microbial genomics2266131UNISA